cevimeline hydrochloride 30 MG Oral Capsule [Evoxac]
cevimeline hydrochloride
RxCUI: 261361
What the CMS Formulary Data Shows for cevimeline hydrochloride 30 MG Oral Capsule [Evoxac]
Per the CMS 2026 Part D formulary file, cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] (RxNorm concept RXCUI 261361, generic name cevimeline hydrochloride) appears on 1 distinct formulary file spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 4 to Tier 4, with a cross-plan average of Tier 4.
Real-world access to cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 26,123 Part D beneficiaries filled cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] in 2023, with total plan-and-beneficiary spending of $22,534,944 and an average per-beneficiary annual cost of $862.65. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 6
- Coverage rate
- 0.1%
- Tier range
- Tier 4, Non-Preferred
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 26,123
- Total spending
- $22,534,944
- Avg per beneficiary
- $862.65
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering cevimeline hydrochloride 30 MG Oral Capsule [Evoxac]
6 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Óptimo Plus (PPO) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
| Contigo Plus (HMO C-SNP) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
| Brillante (HMO-POS) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
| Enlace Plus (HMO) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
| ContigoEnMente (HMO C-SNP) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
| Ahorro Plus (HMO) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
Frequently Asked Questions
Is cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] covered by Medicare Part D?
Yes, cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).
What tier is cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] on Medicare Part D plans?
cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] averages Tier 4 across Part D plans, ranging from Tier 4 to Tier 4.
Does cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] require prior authorization?
0% of Part D formularies require prior authorization for cevimeline hydrochloride 30 MG Oral Capsule [Evoxac]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on cevimeline hydrochloride 30 MG Oral Capsule [Evoxac]?
In 2023, total Medicare Part D spending on cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] was $22,534,944, covering 26,123 beneficiaries. The average spend per beneficiary was $862.65.
Read our methodology - how this data is sourced, computed, and verified.